

# Richard C Kevin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4747340/publications.pdf>

Version: 2024-02-01

40  
papers

1,822  
citations

331670

21  
h-index

302126

39  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1511  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacology of Valinate and <i>tert</i> -Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 2016, 7, 1241-1254.	3.5	214
2	Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 2015, 6, 1546-1559.	3.5	202
3	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 2015, 6, 1445-1458.	3.5	167
4	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 2019, 236, 2713-2724.	3.1	130
5	Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor. Neuropsychopharmacology, 2013, 38, 2249-2259.	5.4	112
6	Effect of Cannabidiol and $\Delta^9$ -Tetrahydrocannabinol on Driving Performance. JAMA - Journal of the American Medical Association, 2020, 324, 2177.	7.4	106
7	Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 437-446.	2.5	69
8	Nabiximols for the Treatment of Cannabis Dependence. JAMA Internal Medicine, 2019, 179, 1242.	5.1	68
9	Synthesis and <i>in Vitro</i> Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chemical Neuroscience, 2020, 11, 4434-4446.	3.5	62
10	Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. ACS Chemical Neuroscience, 2017, 8, 2159-2167.	3.5	53
11	Defensive Aggregation (Huddling) in <i>Rattus Norvegicus</i> toward Predator Odor: Individual Differences, Social Buffering Effects and Neural Correlates. PLoS ONE, 2013, 8, e68483.	2.5	45
12	Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Testing and Analysis, 2019, 11, 279-291.	2.6	45
13	Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 162-171.	2.5	41
14	In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicology, 2017, 35, 333-347.	2.4	35
15	Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Substance Abuse: Research and Treatment, 2017, 11, 117822181770173.	0.9	33
16	Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 414-422.	2.5	33
17	Detection of $\Delta^9$ THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. Drug Testing and Analysis, 2019, 11, 1486-1497.	2.6	32
18	CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist. Frontiers in Pharmacology, 2019, 10, 595.	3.5	32

#	ARTICLE	IF	CITATIONS
19	Parameters That Affect Fear Responses in Rodents and How to Use Them for Management. <i>Frontiers in Ecology and Evolution</i> , 2019, 7, .	2.2	29
20	Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. <i>Forensic Toxicology</i> , 2019, 37, 17-26.	2.4	28
21	Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. <i>Forensic Toxicology</i> , 2015, 33, 355-366.	2.4	26
22	Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice. <i>Behavioural Pharmacology</i> , 2020, 31, 591-596.	1.7	25
23	Citalopram and Cannabidiol. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 525-533.	1.4	24
24	Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2022, 36, 1338-1349.	4.0	23
25	Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. <i>Journal of Psychopharmacology</i> , 2017, 31, 757-769.	4.0	21
26	Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal. <i>Forensic Toxicology</i> , 2017, 35, 33-44.	2.4	19
27	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108220.	3.2	19
28	The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-APY-PICA, 5F-APY-PINACA, and their analogs. <i>Drug Testing and Analysis</i> , 2019, 11, 976-989.	2.6	17
29	Are blood and oral fluid $\Delta^9$ -tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 134, 104433.	6.1	15
30	A validated method for the simultaneous quantification of cannabidiol, $\Delta^9$ -tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial. <i>Drug Testing and Analysis</i> , 2021, 13, 614-627.	2.6	14
31	The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. <i>Drug Testing and Analysis</i> , 2018, 10, 1099-1109.	2.6	12
32	Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. <i>Drug Testing and Analysis</i> , 2018, 10, 137-147.	2.6	11
33	In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 193, 172918.	2.9	11
34	Orally administered cannabidiol does not produce false-positive tests for $\Delta^9$ -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000. <i>Drug Testing and Analysis</i> , 2022, 14, 137-143.	2.6	11
35	Structure-activity relationships of valine, <i>tert</i> -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. <i>RSC Medicinal Chemistry</i> , 2022, 13, 156-174.	3.9	11
36	Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. <i>Sports Medicine - Open</i> , 2022, 8, 27.	3.1	10

#	ARTICLE	IF	CITATIONS
37	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. ACS Chemical Neuroscience, 2021, 12, 4020-4036.	3.5	7
38	Defining Steric Requirements at CB <sub>1</sub> and CB <sub>2</sub> Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS Chemical Neuroscience, 2022, 13, 1281-1295.	3.5	6
39	Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca <sub>v</sub> 3) Inhibitors. ACS Chemical Neuroscience, 2022, 13, 1395-1409.	3.5	4
40	Cannabis: The Pharmacokinetics and Pharmacodynamics of Recreational and Medicinal Cannabis. , 0, , 194-210.		0